Previous 10 |
The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2018 Q4 earnings Read more ...
Acceleron Pharma (NASDAQ: XLRN ): Q4 GAAP EPS of -$0.75 misses by $0.07 . More news on: Acceleron Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- MEDALIST and BELIEVE Phase 3 trial presentations at the 60 th American Society of Hematology (ASH) Annual Meeting both selected for “Best of ASH” - - Luspatercept Biologics License Application (BLA) submission expected in April 2019 - - Part 2 results from the...
AEGN , ALEX , AMED , ANSS , APA , ATSG , AYX , BEL , BGNE , BILI , BKNG , BOLD , BOX , CABO , CCRN , CHDN , COLL , CRC , CVNA , CWK , DAR , ECPG , ERI , ESTC , ESV , FG , FIT , FOE , FTAI , FTSI , GEF , GKOS , HGV , HHC , HPQ , ITRI , KRA , KW , LADR ,...
Acceleron Pharma (NASDAQ: XLRN ) is scheduled to announce Q4 earnings results on Wednesday, February 27th, after market close. The consensus EPS Estimate is -$0.68 (-9.7% Y/Y) and the consensus Revenue Estimate is $3.04M (-18.1% Y/Y). Over the last 2 years, XLRN has beaten EPS estimat...
Acceleron Pharma (NASDAQ: XLRN ) initiated with Outperform rating and $78 (84% upside) price target at Cowen and Company. More news on: Acceleron Pharma Inc., EXACT Sciences Corporation, Kadmon Holdings, Healthcare stocks news, Stocks on the move, , Read more ...
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.m. EST to discuss its fourth quarter and full year 2018 operating and financial results. The webcast will be accessible under "Events & Presentatio...
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will present at two upcoming healthcare investor conferences. ...
News, Short Squeeze, Breakout and More Instantly...
Acceleron Pharma Inc. Company Name:
XLRN Stock Symbol:
NASDAQ Market:
Acceleron Pharma Inc. Website:
Believes Transaction Comes at the Wrong Time, With the Wrong Price, and Following the Wrong Process Remains Confident in Company’s Standalone Opportunities – Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data Stands Ready to Hel...
In September, Merck (NYSE: MRK) announced plans to acquire Acceleron Pharma (NASDAQ: XLRN) for $11.5 billion. However, the big drugmaker recently revealed that it withdrew a key regulatory filing document related to the transaction. In this Motley Fool Live video ...